一个聚 (乙烯基醇) 涂层的核心外纳米粒子,其表面可调节pH和谷二重响应药物输送
Jiagen Li1, Yuhang Hou1, Hao Wu1
1College of Chemistry and Life Science, Sichuan Provincial Key Laboratory for Structural Optimization and Application of Functional Molecules, Chengdu Normal University, Chengdu 611130, China.
Colloids and surfaces. B, Biointerfaces
|December 5, 2024
概括
这项研究开发了双响应的核心外纳米粒子 (PMAA@DOX-PVA),可增强药物负载并减少向癌症治疗的泄漏. 新型纳米粒子在体外显示出改善的生物相容性和增强的抗瘤疗效.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 纳米粒子表面特征对于向药物递送效率至关重要.
- 开发刺激反应系统是克服癌症治疗方面的挑战的关键.
研究的目的:
- 设计一个核心外纳米粒子系统 (PMAA@DOX-PVA) 具有可调的表面特性,用于增强药物输送.
- 为了研究纳米颗粒对pH和谷氨水平的双重反应性.
- 评估开发系统的药物负载,释放动力学,稳定性和体外抗瘤疗效.
主要方法:
- 聚甲基酸 (PMAA) 核心纳米颗粒的合成,载有多克索鲁比 (DOX).
- 聚乙醇 (PVA) 与PMAA核心的共价结合,通过乙烯结.
- 纳米粒子属性的表征,包括药物加载效率和在不同的pH和谷氨酸条件下体外药物释放.
- 使用A549癌细胞进行体外细胞毒性测定,以评估生物相容性和抗瘤活性.
主要成果:
- 药物加载效率从8% (PMAA@DOX) 增加到18% (PMAA@DOX-PVA-0.2). 在这种情况下,药物加载效率从8% (PMAA@DOX) 增加到18% (PMAA@DOX-PVA-0.2).
- 在pH 7.4下,62小时后药物泄漏率从37% (PMAA@DOX) 降至21% (PMAA@DOX-PVA-0.2),表明稳定性有所改善.
- 在不同的环境中,PVA比率显著影响了药物释放概况.
- 空载体显示出优异的生物相容性,而PVA涂层的纳米颗粒增强了对A549细胞的抗瘤功效.
结论:
- 开发的核心外纳米颗粒提供了一个强大的平台,用于控制药物释放,具有可调整的表面特性.
- 对pH和谷氨的双重反应,加上增强的稳定性和有效性,为先进的药物输送提供了一个有前途的战略.
- 这些可定制的纳米颗粒有可能成为下一代多功能药物输送系统,用于各种生物医学应用.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...